Nanoviricides, Inc. shares fall 1.05% after-hours as NV-387's anti-inflammatory effects are reported.

Nanoviricides, Inc. declined 1.05% in after-hours trading, following the company's report on NV-387's anti-inflammatory effects. The drug not only attacks the virus but also reduces inflammation, protecting lungs and minimizing the risk of reawakening cancer. This news, while potentially beneficial for the drug's efficacy, may have caused concern among investors regarding the company's financial stability or other factors not explicitly mentioned in the news.